Apogee Therapeutics’ APG777 antibody demonstrated significant improvement in atopic dermatitis symptoms in Phase 2 trials, reducing eczema severity by 71% compared to placebo. Its longer half-life supports less frequent dosing than existing therapies like Dupixent and Ebglyss, potentially offering a competitive edge. The treatment met primary and secondary endpoints and showed a favorable safety profile, positioning it well for further late-stage development in a crowded eczema market.